ABSTRACT
The COVID-19 disease is an infectious disease caused by the SARS-CoV 2 virus whose clinical presentation is very heterogeneous: it can range from asymptomatic people to critically ill patients, with cytokine storm, acute respiratory distress, organ dysfunction and even death. Current therapies for its treatment are aimed at reducing the impact of the inflammatory cascade, and within these we find hemoadsorption technologies such as the CytoSorb membrane. Next, we present a 31-year-old male patient, who consulted due to severe symptoms of COVID-19 and showed an evident clinical and biochemical improvement after using the CytoSorb device. This is the only documented patient in Colombia who has undergone haemoperfusion therapy with this device in conjunction with prolonged intermittent renal replacement therapy and favorable clinical outcomes have been recorded. © 2021, Asociacion Colombiana de Nefrologia e Hipertension Arterial. All rights reserved.
ABSTRACT
Introduction: COVID-19 is a pneumonia caused by the new SARS-CoV-2 coronavirus, which can present with severe symptoms, acute respiratory distress (ARDS), multiple organ dysfunction and death;as a consequence of a dysregulated inflammatory response called "cytokine storm". Plasmapheresis is proposed as a promising treatment strategy for the management of this type of complications.
ABSTRACT
Introduction: COVID-19 is an infectious disease caused by the RNA SARS-CoV-2 virus, with a high rate of infection and a heterogeneous clinical course. There is evidence that in the advanced phase of COVID-19 there is an increased risk of disseminated intravascular coagulation. Therefore, heparin management should be considered as a therapeutic strategy. Objectives: our main objective is to show the most relevant literature available, with reference to the usefulness of anticoagulation in the management of hypercoagulability in patients with COVID-19 and severe manifestations. Methodology: A narrative review was performed from the advanced search with the terms DeSC: Coronavirus Infections;SARS-CoV;Blood Coagulation;Disseminated intravascular coagulation;Multiple organic dysfunction;Sepsis;Systemic inflammatory response syndrome;Acute kidney injury. The Clinical Key, Embase, PubMed and Ovid search engines were used, obtaining a total of 143 results, among original articles, case reports, case series and literature reviews, a total of 56 articles were selected that were used to the preparation of this topic review. Conclusions: Heparin management should be considered as a therapeutic strategy. We continue with the need for future studies that investigate questions in the hospitalized COVID-19 patient, especially defining, evaluating risk/benefit, which is justified or not with respect to full anticoagulation in some specific patients with COVID-19.